Jianming Xu
A5100726667- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Genetic factors in colorectal cancer
- Fibroblast Growth Factor Research
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- Liver Disease Diagnosis and Treatment
- CAR-T cell therapy research
- Liver physiology and pathology
Chinese PLA General Hospital
2018-2025
Second Affiliated Hospital of Guangzhou Medical University
2024-2025
First Affiliated Hospital of Wenzhou Medical University
2025
Second Affiliated Hospital of Nanchang University
2025
Nanchang University
2025
Wuhan Donghu University
2025
Wuhan University
2025
Weifang Maternity and Child Care Hospital
2025
Shantou University
2024
Chinese University of Hong Kong
2024
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in gastroesophageal junction adenocarcinoma whom at least prior chemotherapy had failed. Patients Methods This was randomized, double-blind, placebo-controlled phase III trial. from 32 centers...
Purpose Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods were stratified randomly assigned receive 37.5 mg once per day 400 twice day. Primary end point overall survival (OS). Results Early termination occurred for futility safety reasons. A total of 1,074 patients the study (sunitinib arm, n = 530; 544). For sorafenib, respectively, median OS 7.9 versus 10.2 months (hazard ratio [HR], 1.30;...
Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast receptors that are implicated in the pathogenesis hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC.Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive 400 mg twice daily orally (n = 578) or 800 once 577). Primary end point was overall survival (OS)....
<b><i>Background:</i></b> Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and second leading cause of tumor-related death, thereby posing a significant threat to life health Chinese people. <b><i>Summary:</i></b> Since publication <i>Guidelines for Diagnosis Treatment Liver Cancer (2017 Edition)</i> 2018, additional high-quality evidence has emerged with relevance...
Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) –positive tumors. The role of anti-HER2 agents, lapatinib, this setting and population unclear. Patients Methods TyTAN was a two-part, parallel-group, phase III study patients. An open-label, dose-optimization (n = 12) followed by randomized 261), which patients who were HER2 positive fluorescence situ hybridization (FISH)...
To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.Patients HER2-positive adenocarcinoma were randomly assigned at a one-to-one ratio CapeOx plus 1,250 mg or placebo daily. Primary end point was overall survival (OS) centrally confirmed HER2 amplification primary population.A total 545 assigned, 487 comprised population....
Patients with metastatic gastric cancer (mGC) who do not respond to or experience progression second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor vascular endothelial growth factor receptor, as option for heavily pretreated patients mGC.Patients experienced failure at least two chemotherapeutic regimens were randomly assigned receive placebo (group A), apatinib 850 mg once daily...
We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).This nonrandomized, open-label, multicenter, phase II study enrolled HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous 200 mg (for bodyweight ≥50 kg) 3 mg/kg <50 every 2 weeks oral 250 daily. The primary endpoint was objective...
The AVAGAST study showed that adding bevacizumab to chemotherapy in patients with advanced gastric cancer improves progression-free survival and tumor response rate but not overall survival. To examine the hypothesis angiogenic markers may have predictive value for efficacy cancer, included a prospective, mandatory biomarker program.Patients previously untreated, locally or metastatic were randomly assigned (n = 387) placebo combination chemotherapy. Blood tissue samples collected at...
First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over previously treated patients with carcinoma.In this open-label, phase 3 trial, we randomly assigned adults untreated, unresectable advanced, recurrent, or metastatic a 1:1:1 ratio to receive plus chemotherapy, the ipilimumab, chemotherapy. primary end points were and progression-free survival, as determined by blinded...
<h3>Importance</h3> Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. <h3>Objective</h3> To evaluate the efficacy safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients CRC. <h3>Design, Setting, Participants</h3> FRESCO (Fruquintinib Efficacy Safety 3+ Line Colorectal Cancer Patients) was randomized, double-blind, placebo-controlled, multicenter (28...
The diffuse-type gastric cancer (DGC) is a subtype of with the worst prognosis and few treatment options. Here we present dataset from 84 DGC patients, composed proteome 11,340 gene products mutation information 274 driver genes covering paired tumor nearby tissue. can be classified into three subtypes (PX1-3) based on altered alone. PX1 PX2 exhibit dysregulation in cell cycle features an additional EMT process; PX3 enriched immune response proteins, has survival, insensitive to...
Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil Asian mCRC or without exposure to biologic therapy. Patients Methods randomized, double-blind, placebo-controlled, III conducted at 30 sites China, Republic Korea, Thailand. ≥ 18 years old histologically cytologically confirmed adenocarcinoma colon rectum known KRAS status who...
Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients